415.jpg)
The efficacy of COVID-19 vaccines against the new variant Omicron may be reduced due to the presence of over 30 mutations at the spike protein of the virus, AIIMS chief Dr Randeep Guleria has said. The virus variant has the potential of developing "immunoescape mechanisms", Dr Guleria said. Most vaccines work by developing antibodies against the spike protein, he added.
The efficacy of COVID-19 vaccines against the new variant Omicron may be reduced due to the presence of over 30 mutations at the spike protein of the virus, AIIMS chief Dr Randeep Guleria has said. The virus variant has the potential of developing "immunoescape mechanisms", Dr Guleria said. Most vaccines work by developing antibodies against the spike protein, he added.
